Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tTF-NGR in Recurrent or Refractory Malignant Tumors and Lymphomas
NCT02902237Phase 1Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Immunotoxins, Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tTF-NGR in malignant solid tumor and lymphoma, sponsored by Universitätsklinikum Münster. Primary endpoints: Maximum Tolerated Dose up to 3 months and Dose-Limiting Toxicity up to 3 months. Started Mar 2017; status: completed.
02
Drugs
tTF-NGR
03
Conditions
malignant solid tumorlymphoma
Beyond the preview
Go deeper on NCT02902237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902237.